Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

Journal of clinical psychopharmacology - 1 Aug 2009

Nichols Alice I, Lobello Kasia, Guico-Pabia Christine J, Paul Jeff, Preskorn Sheldon H

Abstract excerpt

INTRODUCTION: One of the major enzymes of the cytochrome P450 drug-metabolizing system, CYP2D6, shows a high degree of genetic polymorphism and variability in activity. Based on the degree of CYP2D6 activity, individuals can be broadly classified as poor metabolizers (PMs) or extensive metabolizers (EMs); the metabolism of CYP2D6 substrates differs among PMs and EMs. The metabolism of various drugs that are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cyclohexanols

Share to Cytochrome P-450 CYP2D6

Share to Selective Serotonin Reuptake Inhibitors

Share to Substrate Specificity

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 19593180
DOI: 10.1097/JCP.0b013e3181acc4dd

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.PMID 19593180Read ↗

Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.Semantic proximity Read ↗

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.Semantic proximity Read ↗

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.Semantic proximity Read ↗

Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.Semantic proximity Read ↗

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.Semantic proximity Read ↗

Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.Semantic proximity Read ↗

The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.Semantic proximity Read ↗

An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity Read ↗

Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.Semantic proximity Read ↗

The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.Semantic proximity Read ↗

Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.